ACC 2019 Highlights: TAVR, Electrophysiology, Anti-thrombotic Therapies

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

ACC 2019 Highlights: TAVR, Electrophysiology, Anti-thrombotic Therapies

By Cleveland Clinic Heart, Vascular and Thoracic Institute

23 views

October 29, 2019

A. Michael Lincoff, MD, Director of the Cleveland Clinic Coordinating Center for Clinical Research, reviews ...
read more ↘ the results from clinical trials presented at the 2019 American College of Cardiology Conference focusing on three major practice areas: 1) the use of transcatheter aortic valves (TAVR) in low risk patients (PARTNER 3, Evolut Low) ; 2) electrophysiology studies (Apple Heart, WRAP-IT) ; and 3) anti-thrombotic therapies in patients with atrial fibrillation, acute coronary syndrome or percutaneous intervention (AUGUSTUS, GLASSY). Dr. Lincoff summarizes the studies’ design and results, and provides insight into the potential impact on future care of patients based on these outcomes.
↖ read less

0 Comments